The DOI matches its Crossref record.
Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( R )-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults
Open accessAbstract
9-[2-( R )-(Phosphonomethoxy)propyl]adenine (PMPA) is a nucleotide analogue with potent antiretroviral activity in vitro and in simian models. A randomized, double-blind, placebo-controlled, dose-escalation clinical trial of intravenous PMPA monotherapy was conducted in 20 human immunodeficiency virus (HIV)-infected adults with CD4 cell counts of ≥200 cells/mm 3 and plasma HIV RNA levels of ≥10,000 copies/ml. Two dose levels were evaluated (1 and 3 mg/kg of body weight/day). Ten subjects were enrolled at each dose level (eight randomized to receive PMPA and two randomized to receive placebo). On day 1, a single dose of PMPA or placebo was administered by intravenous infusion. Beginning on study day 8, PMPA or placebo was administered once daily for an additional 7 consecutive days. All subjects tolerated dosing without significant adverse events. Mean peak serum PMPA concentrations were 2.7 ± 0.9 and 9.1 ± 2.1 μg/ml in the 1- and 3-mg/kg cohorts, respectively. Serum concentrations declined in a biexponential fashion, with a terminal half-life of 4 to 8 h. At 3 mg/kg/day, a single infusion of PMPA resulted in a 0.4 log 10 median decline in plasma HIV RNA by study day 8. Following 7 consecutive days of study drug administration thereafter, the median changes in plasma HIV RNA from baseline were −1.1, −0.6, and 0.1 log 10 in the 3-mg/kg/day, 1-mg/kg/day, and placebo dose groups, respectively. Following the final dose in the 3-mg/kg/day cohort, the reduction in HIV RNA was sustained for 7 days before returning toward baseline. Further studies evaluating an oral prodrug of PMPA are under way.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics
Kearney, B. P., Flaherty, J. F., & Shah, J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443090-00003 · Cited by 456
Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase
Johnson, A. A., Ray, A. S., Hanes, J., Suo, Z., Colacino, J. M., Anderson, K. S., & Johnson, K. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106743200 · Cited by 403
Ray, A. S., Fordyce, M. W., & Hitchcock, M. J. M. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2015.11.009 · Cited by 392
De Clercq, E. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.4.569-596.2003 · Cited by 369
Fanconi syndrome and renal failure induced by tenofovir: A first case report
Verhelst, D., Monge, M., Meynard, J.-L., Fouqueray, B., Mougenot, B., Girard, P.-M., Ronco, P., & Rossert, J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.36924 · Cited by 349
Metadata
- Authors
- Deeks, S. G., Barditch-Crovo, P., Lietman, P. S., Hwang, F., Cundy, K. C., Rooney, J. F., Hellmann, N. S., Safrin, S., & Kahn, J. O.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-09
- Volume
- 42
- Issue
- 9
- Pages
- 2380-2384
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1789897256
- Cited by
- 158
- References
- 0
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( R )-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults. https://app.cochat.ai/papers/10.1128/aac.42.9.2380
- The paper
- Deeks, S. G., Barditch-Crovo, P., Lietman, P. S., Hwang, F., Cundy, K. C., Rooney, J. F., Hellmann, N. S., Safrin, S., & Kahn, J. O. (1998). Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( R )-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.42.9.2380
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.